Evaluation and Management of Bilateral Pulmonary Ground Glass Opacities

Definition and Classification

Bilateral pulmonary ground glass opacities (GGOs) should be evaluated with a structured diagnostic approach beginning with detailed characterization of the GGO pattern, followed by high-resolution CT (HRCT) to determine distribution and associated features, with follow-up imaging in 2-3 years for interstitial lung abnormalities (ILAs) 1
Nondependent bilateral GGOs may represent interstitial lung abnormalities (ILAs) when involving ≤5% of a lung zone 1, 2
Dependent GGOs should be confirmed with prone imaging to rule out atelectasis 1
Peripheral or peribronchovascular distribution may suggest organizing pneumonia pattern 3

Determine if GGOs are associated with other radiographic findings, such as reticular abnormalities, traction bronchiectasis, or honeycombing, which suggest fibrotic process 1, 4
Mosaic attenuation pattern may suggest pulmonary edema, hypersensitivity pneumonitis, or chronic thromboembolic disease 5
Part-solid nodules (GGO with solid component) require more aggressive evaluation than pure GGOs 6
Evaluate for specific patterns that suggest particular diagnoses, such as nonspecific interstitial pneumonia (NSIP), organizing pneumonia (OP), hypersensitivity pneumonitis (HP), or diffuse alveolar damage (DAD) 3

Follow-up chest CT scan 2-3 years after baseline for interstitial lung abnormalities (ILAs) 1, 2
Monitor for progression to more extensive disease patterns or development of fibrotic changes 7
For part-solid nodules ≤8 mm, low-dose CT surveillance at 3, 12, and 24 months is recommended 6
For part-solid nodules >8 mm, repeat CT at 3 months and consider empiric antimicrobial therapy if clinically appropriate 6

Idiopathic interstitial pneumonias, such as nonspecific interstitial pneumonia (NSIP) and organizing pneumonia (OP), should be considered 3, 8
Inflammatory conditions, such as hypersensitivity pneumonitis and connective tissue disease-related lung disease, should be evaluated 3, 7
Drug-induced pneumonitis, including EGFR-TKI therapy, mTOR inhibitors, and immune checkpoint inhibitors, should be considered 3
Infectious etiologies, such as viral pneumonia (including COVID-19), should be evaluated 9
Pulmonary edema (hydrostatic or permeability-related) should be considered 10

GGOs in dependent lung regions on supine imaging may represent atelectasis rather than true pathology - confirm with prone imaging 1
Bilateral GGOs with mosaic attenuation in COVID-19 may be present even in asymptomatic patients 9
Subtle GGOs may represent early disease that could progress if not appropriately managed, highlighting the importance of follow-up 7